UA99265C2 - Способ получения 1,2,4-оксадиазолбензойной кислоты и ее производных (варианты) - Google Patents

Способ получения 1,2,4-оксадиазолбензойной кислоты и ее производных (варианты)

Info

Publication number
UA99265C2
UA99265C2 UAA200903350A UAA200903350A UA99265C2 UA 99265 C2 UA99265 C2 UA 99265C2 UA A200903350 A UAA200903350 A UA A200903350A UA A200903350 A UAA200903350 A UA A200903350A UA 99265 C2 UA99265 C2 UA 99265C2
Authority
UA
Ukraine
Prior art keywords
processes
preparation
benzoic acid
derivatives
oxadiazole benzoic
Prior art date
Application number
UAA200903350A
Other languages
English (en)
Ukrainian (uk)
Inventor
Нил Г. АЛЬМСТЕД
Питер Сеонгвоо Хванг
Симон ПАЙНЗ
Йоунг-Чоон Моон
Джеймс Дж. ТАКАСУГИ
Original Assignee
ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ПиТиСи ТЕРАПЬЮТИКС, ИНК. filed Critical ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Publication of UA99265C2 publication Critical patent/UA99265C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Предложены способы получения соединений, которые применяют для лечения, профилактики или устранения заболеваний, связанных с нонсенс-мутацией. Более конкретно, предложены способы синтеза 1,2,4-оксадиазолов. В частности, предложены способы получения 3-[5-(2-фторфенил[1,2,4]оксадиазол-3-ил]бензойной кислоты.
UAA200903350A 2006-09-08 2007-09-06 Способ получения 1,2,4-оксадиазолбензойной кислоты и ее производных (варианты) UA99265C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84359506P 2006-09-08 2006-09-08

Publications (1)

Publication Number Publication Date
UA99265C2 true UA99265C2 (ru) 2012-08-10

Family

ID=38935880

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200903350A UA99265C2 (ru) 2006-09-08 2007-09-06 Способ получения 1,2,4-оксадиазолбензойной кислоты и ее производных (варианты)

Country Status (25)

Country Link
US (2) US7678922B2 (ru)
EP (1) EP2059513B1 (ru)
JP (2) JP5955494B2 (ru)
KR (1) KR101466368B1 (ru)
CN (1) CN101535284B (ru)
AR (3) AR062715A1 (ru)
AU (1) AU2007292915B2 (ru)
BR (1) BRPI0716996B8 (ru)
CA (2) CA2842625C (ru)
CL (1) CL2007002606A1 (ru)
DK (1) DK2059513T3 (ru)
ES (1) ES2404348T3 (ru)
HK (1) HK1134094A1 (ru)
IL (1) IL197445A (ru)
MX (1) MX2009002439A (ru)
MY (1) MY148598A (ru)
NZ (2) NZ575511A (ru)
PE (2) PE20120669A1 (ru)
PL (1) PL2059513T3 (ru)
PT (1) PT2059513E (ru)
RU (1) RU2495030C2 (ru)
TW (1) TWI482761B (ru)
UA (1) UA99265C2 (ru)
WO (1) WO2008030570A1 (ru)
ZA (1) ZA200901782B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2926542T3 (es) 2003-04-11 2022-10-26 Ptc Therapeutics Inc Compuestos de ácido 1,2,4-oxadiazol benzoico y su uso para supresión de mutaciones finalizadoras y el tratamiento de enfermedades
CA2603402C (en) 2005-04-08 2017-10-31 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
SG170819A1 (en) 2006-03-30 2011-05-30 Ptc Therapeutics Inc Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
RU2495030C2 (ru) * 2006-09-08 2013-10-10 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы получения 1,2,4-оксадиазолбензойных кислот
WO2008130370A1 (en) 2006-09-25 2008-10-30 Ptc Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression
MX2009003160A (es) 2006-09-25 2009-04-06 Ptc Therapeutics Inc Formas cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol -3-il]-benzoico.
RU2462247C2 (ru) 2006-10-12 2012-09-27 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы дозирования перорально активного 1,2,4-оксадиазола для терапии, подавляющей нонсенс-мутацию
CN101714009A (zh) * 2009-05-14 2010-05-26 翁印嵩 集成通用电话功能的计算机
WO2012101292A1 (es) 2011-01-25 2012-08-02 Viviabiotech, S.L. Derivados de 1,2,4-oxadiazol como fármacos moduladores del receptor para el péptido glp-1
WO2014008257A2 (en) 2012-07-02 2014-01-09 Monsanto Technology Llc Processes for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles
CA3174516A1 (en) 2014-03-06 2015-09-11 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
CN105461650B (zh) * 2014-09-12 2018-04-13 杭州普晒医药科技有限公司 一种噁二唑化合物的溶剂化物及其制备方法
CN106316885B (zh) * 2015-07-03 2019-02-12 普济生物科技（台州）有限公司 一种3-[5-(2-氟苯基)-1,2,4-噁二唑-3-基]苯甲酸的制备方法
MX2018005361A (es) 2015-10-30 2018-06-07 Ptc Therapeutics Inc Metodos para tratar epilepsia.
TW201808922A (zh) 2016-06-20 2018-03-16 台灣神隆股份有限公司 製備阿塔魯仁及其中間體的方法
US20220071965A1 (en) 2018-12-20 2022-03-10 Pfizer Inc. Pharmaceutical Compositions and Methods Comprising A Combination of a Benzoxazole Transthyretin Stabilizer and an Additional Therapeutic Agent
WO2022112919A1 (en) 2020-11-25 2022-06-02 Pfizer Inc. (aza)benzothiazolyl substituted pyrazole compounds
CN113045510B (zh) * 2021-03-31 2022-05-27 北京大学生命科学华东产业研究院 一种阿塔鲁伦的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2801509A1 (de) * 1978-01-12 1979-07-19 Schering Ag 1,2,4-oxadiazolderivate, verfahren zur herstellung dieser verbindungen sowie diese enthaltende selektive herbizide mittel
DE3905242A1 (de) * 1989-02-21 1990-08-23 Basf Ag Verfahren zur herstellung von phenyloxdiazolylanilinen
NZ234760A (en) * 1989-08-18 1991-09-25 Sterling Drug Inc Antiviral oxazole compounds and compositions
DE4425794A1 (de) * 1994-07-21 1996-01-25 Basf Ag Nitrofarbstoffe
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
IL159086A0 (en) * 2001-06-08 2004-05-12 Cytovia Inc 3-aryl-5-aryl- [1, 2, 4] -oxadiazole derivatives and pharmaceutical compositions containing the same
MY151199A (en) * 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
WO2004014370A2 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Oxadiazoles as modulators of metabotropic glutamate receptor-5
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
ES2926542T3 (es) * 2003-04-11 2022-10-26 Ptc Therapeutics Inc Compuestos de ácido 1,2,4-oxadiazol benzoico y su uso para supresión de mutaciones finalizadoras y el tratamiento de enfermedades
US20050075375A1 (en) * 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
CA2603402C (en) * 2005-04-08 2017-10-31 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
RU2495030C2 (ru) * 2006-09-08 2013-10-10 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы получения 1,2,4-оксадиазолбензойных кислот

Also Published As

Publication number Publication date
ES2404348T3 (es) 2013-05-27
BRPI0716996A2 (pt) 2013-10-08
DK2059513T3 (da) 2013-05-06
US20100063297A1 (en) 2010-03-11
JP2014193896A (ja) 2014-10-09
US7678922B2 (en) 2010-03-16
AR118922A2 (es) 2021-11-10
NZ598012A (en) 2013-08-30
TWI482761B (zh) 2015-05-01
US20080139818A1 (en) 2008-06-12
HK1134094A1 (en) 2010-04-16
AU2007292915B2 (en) 2012-07-26
CA2842625A1 (en) 2008-03-13
RU2495030C2 (ru) 2013-10-10
TW200823180A (en) 2008-06-01
MX2009002439A (es) 2009-03-27
NZ575511A (en) 2012-02-24
EP2059513B1 (en) 2013-01-23
PE20120669A1 (es) 2012-06-01
CA2662749A1 (en) 2008-03-13
AU2007292915A1 (en) 2008-03-13
AR062715A1 (es) 2008-11-26
IL197445A0 (en) 2009-12-24
CA2842625C (en) 2016-07-12
US8367841B2 (en) 2013-02-05
ZA200901782B (en) 2010-06-30
JP2010502715A (ja) 2010-01-28
PE20080771A1 (es) 2008-06-13
EP2059513A1 (en) 2009-05-20
CN101535284B (zh) 2014-12-10
CA2662749C (en) 2015-01-20
KR20090054464A (ko) 2009-05-29
JP5955494B2 (ja) 2016-07-20
CL2007002606A1 (es) 2008-04-18
PT2059513E (pt) 2013-04-30
BRPI0716996B8 (pt) 2021-05-25
WO2008030570A1 (en) 2008-03-13
IL197445A (en) 2014-01-30
AR107474A2 (es) 2018-05-02
BRPI0716996B1 (pt) 2021-02-09
RU2009113019A (ru) 2010-10-20
MY148598A (en) 2013-05-15
PL2059513T3 (pl) 2013-06-28
KR101466368B1 (ko) 2014-11-27
CN101535284A (zh) 2009-09-16

Similar Documents

Publication Publication Date Title
UA99265C2 (ru) Способ получения 1,2,4-оксадиазолбензойной кислоты и ее производных (варианты)
MX2009003909A (es) Métodos para dosificar un compuesto 1,2,4, - oxadiazol oralmente activo para el tratamiento de supresión de la mutación finalizadora.
SG10201609581TA (en) Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
IL199673A0 (en) 5-(1,3,4- oxadiazol-2-yl)-1h-indazole and 5-(1,3,4 thiadiazol-2-yl)-1h-indazole derivatives as sgk inhibitors for the treatment of diabetes
NO2015002I2 (no) Ataluren (3-[5-(2-fluorfenyl)-[ 1,2,4]oksadiazol-3-yl]-benzosyre) og farmasøytisk akseptable salter og solvater derav
HRP20130891T1 (en) DGAT inhibitor
NO20075682L (no) Sammensetninger omfattende et oralt aktivt 1,2,4-oksadiazol for nonsense mutasjonsundertrykkelsesterapi
WO2007039122A3 (de) Feste, oral applizierbare pharmazeutische darreichungsformen mit schneller wirkstofffreisetzung
NZ592792A (en) Heterocyclically substituted aryl compounds as hif inhibitors
WO2005060940A3 (de) Verfahren zur herstellung einer festen, oral applizierbaren pharmazeutischen zusammensetzung
PL2947072T3 (pl) 1-(3-(6,7-dimetoksychinazolin-4-yloksy)fenylo)-3-(5-(1,1,1-trifluoro-2-metylopropan-2-ylo)izoksazol-3-ilo)mocznik jako modulator kinazy RAF w leczeniu chorób nowotworowych
UA88938C2 (ru) Твердые фармацевтические формы для перорального введения, которые содержат ривароксабан, с модифицированным высвобождением
MY151452A (en) Triazole derivative
AR061332A1 (es) Compuesto de oxadiazol como inhibidor de dgat1(diacilglicerol aciltransferasa)
ZA200806891B (en) Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders
WO2010123959A3 (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
MX2010007426A (es) Composiciones farmaceuticas para tratar trastorno del higado graso.
MX2009001977A (es) Derivados profarmacologicos de aminoacilo y medicamentos para el tratamiento de enfermedades tromboembolicas.
WO2008065123A3 (en) Polymorphic forms of deferasirox ( icl670a)
TW200833323A (en) Prophylactic or therapeutic agent for alopecia
CY1113938T1 (el) Διαδικασιες για την παρασκευη 1,2,4-οξαδιαζολο βενζοϊκων οξεων
MD4080C1 (ru) Приминение молсидомина для предотвращения или замедления развития атеросклероза